Ex-Pfizer R&D Chief Warns of Biopharma's Future Risks
The former head of Pfizer R&D expresses concern about the future of the biopharma industry, highlighting past optimism about a productivity surge driven by genomic advances and new drug modalities, but implying that these expectations may not have been realized as hoped.